Analyst consensus rating
ACADIA Pharmaceuticals Analyst Rating: Buy
Direct answer
ACADIA Pharmaceuticals's consensus rating is Buy.
19 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.53.
Forecast evidence checked November 4, 2026.
Get free ACADIA Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $20.57
- Average price target
- $30.53
- High price target
- $37.00
- Low price target
- $16.00
- Low target gap
- -22.2%
- Target upside
- +48.4%
- High target gap
- +79.9%
- Target range width
- 102.1%
- Consensus rating
- Buy
- Analysts
- 19
- Evidence date
- November 4, 2026
- Valid through
- November 11, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $30.53.
How far are ACADIA Pharmaceuticals's low and high targets from the recorded price?
The low target implies -22.2%, while the high target implies +79.9%.
How many analysts are included in ACADIA Pharmaceuticals's consensus?
The verified consensus includes 19 analysts.
How is ACADIA Pharmaceuticals's target upside or downside calculated?
The average target of $30.53 is divided by the recorded price of $20.57, then one is subtracted to produce +48.4%. This does not guarantee a future return.
When was ACADIA Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-11-04. The dataset is valid through 2026-11-11.